Enochian Biosciences Inc ENOB:NASDAQ

Last Price$2.77NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22

Today's Change+0.10(3.75%)
Bid (Size)$2.77 (2)
Ask (Size)$2.86 (3)
Day Low / High$2.59 - 2.85
Volume63.1 K
 

View Biotechnology IndustryPeer Comparison as of 08/12/2022

 

Enochian Biosciences Inc ( NASDAQ )

Price: $2.77
Change: +0.10 (3.75%)
Volume: 63.1 K
4:00PM ET 8/12/2022
 
 

Co-Diagnostics Inc ( NASDAQ )

Price: $4.48
Change: -1.98 (30.65%)
Volume: 4.1 M
4:00PM ET 8/12/2022
 
 

Armata Pharmaceuticals Inc ( NYSE MKT LLC )

Price: $4.22
Change: -0.03 (0.71%)
Volume: 222.00
8:00PM ET 8/12/2022
 
 

La Jolla Pharmaceutical Co ( NASDAQ )

Price: $6.21
Change: +0.01 (0.16%)
Volume: 62.4 K
4:00PM ET 8/12/2022
 
 

Harvard Bioscience Inc ( NASDAQ )

Price: $3.28
Change: -0.01 (0.30%)
Volume: 142.5 K
4:00PM ET 8/12/2022
 

Read more news Recent News

Insider Sell: Enochian Biosciences
7:23AM ET 5/23/2022 MT Newswires

Serhat Gumrukcu, 10% Owner, on May 18, 2022, sold 253,493 shares in Enochian Biosciences (ENOB) for $2,027,944. Following the Form 4 filing with the SEC,...

Insider Buy: Enochian Biosciences
7:22AM ET 5/23/2022 MT Newswires

Rene Sindlev, 10% Owner, Director, on May 18, 2022, executed a purchase for 253,493 shares in Enochian Biosciences (ENOB) for $2,027,944. Following the...

Sector Update: Health Care Stocks Lower In Monday's Premarket Activity
9:15AM ET 2/14/2022 MT Newswires

Health care stocks were lower premarket Monday. The Health Care SPDR (XLV) was down by 0.03% and the iShares Biotechnology ETF (IBB) was slipping by 0.39%...

Enochian Biosciences Files for Shelf Offering of Up to $100 Million Common Shares
3:11AM ET 2/14/2022 MT Newswires

Enochian Biosciences (ENOB) late Friday registered with the US Securities and Exchange Commission for a shelf offering of up to $100 million of common...

View all Commentary and Analysis

No news stories available at this time.

Company Profile

Business DescriptionEnochian Biosciences, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA. View company web site for more details
Address2080 Century Park East
Los Angeles, California 90067-2012
Phone+1.305.918.1980
Number of Employees4
Recent SEC Filing08/03/20224
Executive Vice Chairman & Chief Executive OfficerMark Richard Dybul
Chief Financial OfficerLuisa Puche
Senior Vice President-Clinical OperationsGreg Duczynski
Executive Vice President-Research & DevelopmentFran├žois Binette

Company Highlights

Price Open$2.65
Previous Close$2.67
52 Week Range$1.42 - 13.78
Market Capitalization$146.7 M
Shares Outstanding52.9 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement09/23/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.67
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-24.27%